Ropinirole Cotreatment Prevents Perivascular Glial Recruitment in a Rat Model of L-DOPA-Induced Dyskinesia
Dopamine replacement therapy for Parkinson’s disease is achieved using L-DOPA or dopamine D2/3 agonists, such as ropinirole. Here, we compare the effects of L-DOPA and ropinirole, alone or in combination, on patterns of glial and microvascular reactivity in the striatum. Rats with unilateral 6-hydro...
Main Authors: | Osama F. Elabi, Elena Espa, Katrine Skovgård, Silvia Fanni, Maria Angela Cenci |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-07-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/12/14/1859 |
Similar Items
-
Multimodal imaging study of the 5-HT1A receptor biased agonist, NLX-112, in a model of L-DOPA-induced dyskinesia
by: Sarah Chaib, et al.
Published: (2023-01-01) -
Interactions Between the Serotonergic and Other Neurotransmitter Systems in the Basal Ganglia: Role in Parkinson’s Disease and Adverse Effects of L-DOPA
by: Ana Muñoz, et al.
Published: (2020-06-01) -
Dopamine-Depleted Dopamine Transporter Knockout (DDD) Mice: Dyskinesia with L-DOPA and Dopamine D1 Agonists
by: Vladimir M. Pogorelov, et al.
Published: (2023-11-01) -
Pharmacogenetics of drug-induced dyskinesias in Parkinson's disease
by: A. A. Tappakhov, et al.
Published: (2020-02-01) -
Levodopa-Induced Dyskinesia in Parkinson’s Disease: Pathogenesis and Emerging Treatment Strategies
by: Destany K. Kwon, et al.
Published: (2022-11-01)